US EditionBeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
4 Articles
4 Articles
The American John Oyler, founder and CEO of BeOne, wants to expand more in Europe with cancer medicines. However, China played a central role, especially in the early days of the company.
With the establishment of BeOne Medicines, Switzerland's three largest pharmaceutical companies are based in Basel
BeiGene rebrands, shifts global base to Switzerland
Last summer, BeiGene launched its $800 million U.S. flagship facility in Hopewell. Now, that building is sporting a new name. The global oncology company announced May 27 that it rebranded as BeOne Medicines Ltd. Additionally, the firm’s shareholders also approved its redomiciliation to Switzerland from the Cayman Islands. Both actions passed April 28. “BeOne represents more than a name change—it’s not only a reflection of who we are today as …
Coverage Details
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
